Valsartan Recall Expands: Mylan Recalls Over 100 Lots

Pharmaceutical company Mylan is recalling some of its blood pressure medications due to cancer concerns. The medications recalled all contain Valsartan. Since July 2018, the FDA has been recalling Valsartan due to finding trace amounts of N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA), which are classified as probable human carcinogens by the Environmental Protection Agency.

Mylan has recalled a total of 119 lots of medication containing Valsartan, including Amlodipine and Valsartan Tablets, Valsartan Tablets, and Hydrochlorothiazide Tablets. The list of all recalled lots can be found here.

This is the largest recall in FDA history. Mylan joins a growing number of companies that have recalled lots that contain Valsartan, Irbesartan, and Losartan due to carcinogen contamination. GoldenbergLaw is committed to holding these pharmaceutical companies accountable. If you or a loved one has taken Valsartan, Irbesartan, or Losartan and have been diagnosed with cancer, contact GoldenbergLaw.

Losartan Recalled: List of Recalled Sartan Drugs Continues to Grow

On November 9, 2018, the FDA issued a recall of Losartan due to carcinogen contamination concerns. Losartan is now the third “sartan” drug that has been recalled after the carcinogen N-Nitrosodiethylamine (NDEA) was detected in its active pharmaceutical ingredient.

The recalled lots of Losartan were manufactured by Zhejiang Huahai Pharmaceutical Co. Ltd., the same company that manufactured the NDMA-contaminated Valsartan. Since then, the FDA has put Zhejiang Huahai Pharmaceutical on an import alert, meaning the FDA “has enough evidence to allow for Detention Without Physical Examination of products that appear to be in violation of FDA laws and regulations.”

NDEA is a probable human carcinogen and can cause:

  • Liver cancer
  • Kidney cancer
  • Pancreatic cancer
  • Stomach cancer
  • Colon/colorectal/intestinal cancer
  • Bladder cancer

If you or a loved one contracted liver, kidney, pancreatic, stomach, colorectal, or bladder cancer after taking Losartan, contact GoldenbergLaw. Leave the sleepless nights to us.


Five Things You Should Know About NDMA Contamination in Valsartan

Numerous lots of the drug Valsartan have recently been recalled by the FDA due to NDMA contamination. Read below to learn what you should know about this contamination and FDA recall.

1. What is NDMA?

N-nitrosodimethylamine (NDMA) is a probable human carcinogen classified by the Environmental Protection Agency (EPA) as a semi-volatile organic chemical. Changes to the process used to manufacture Valsartan led to dangerous NDMA contamination of the drug.

2. Which Lots of Valsartan Were Recalled?

The list of Valsartan lots recalled due to dangerous NDMA contamination continues to grow. The FDA continues to update this list to reflect the specific lots included in the Valsartan recall.

3. What Types of Cancer Does Valsartan Cause?

NDMA may increase the risk of developing cancerous tumors. Research has shown that NDMA is linked to liver, kidney, pancreatic, stomach, and colorectal cancer.

4. Where Are the Drugs Coming From?

The NDMA-contaminated Valsartan was produced by three facilities: Zhejiang Huahai Pharmaceuticals in China, Hetero Labs Limited in India, and Zhejiang Tianyu in China.

5. What Should I Do Now?

If you or a loved one took Valsartan and was later diagnosed with cancer, contact GoldenbergLaw for a free consultation. We have over 30 years of experience in product liability litigation, and our attorneys hold several leadership positions in major drug and device lawsuits across the country. Call us. Leave the sleepless nights to us.

Helpful Links:

Fact Sheet about NDMA from the Environmental Protection Agency

Recalled Valsartan products from the FDA: